Craig Okada
CURRICULUM VITAE
OREGON HEALTH & SCIENCE UNIVERSITY
NAME |
Okada, Craig Yoshitsugu |
DATE |
Nov. 28 2022 | |
PRESENT POSITION AND ADDRESS | ||||
Academic Rank: |
Associate Professor | |||
Department/Division: |
Internal Medicine/Hematology and Medical Oncology | |||
Professional Address: |
Oregon Health & Science University | |||
E-Mail Address: |
okadac@ohsu.edu | |||
| ||||
II. EDUCATION | ||||
Undergraduate and Graduate (Include Year, Degree, and Institution):
9/1978 - 6/1982 Honors B.S in Biology University of Utah, Salt Lake, UT
Postgraduate (Include Year, Degree, and Institution):
9/1982 - 6/1990 M.D in Medicine Stanford University, Stanford, CA
9/1982 - 6/1990 Ph.D in Cancer Biology Stanford University, Stanford, CA
Postgraduate Training (Include Year, Specialty, and Institution):
7/1990 - 6/1992 Internal Medicine Residency Stanford University, Stanford, CA
7/1992 - 6/1994 Hematology Clinical Fellowship Stanford University, Stanford, CA
7/1994 - 8/1998 Hematology Research Fellowship Stanford University, Stanford, CA
Certification (Include Board, Number, Date, and Recertification):
National Board of Medical Examiners Number Number 334838 7/1/1991
Diplomat, American Board of Internal Medicine Number 150424 1995 - 2005
Diplomat, Subspecialty of Hematology Number 150424 1996 - 2006
Diplomat, Subspecialty of Hematology – Recert Number 150424 2007 – 2017
Diplomat, Subspecialty of Hematology – Recert Number 150424 2018 – 2027
Licenses (Include State, Date, Status, Number, and Renewal Date):
California 1/14/1992 - 11/30/07 Inactive Number G73270
Michigan 7/21/1998 - 9/31/2005 Inactive Number 4301073111
Oregon 7/09/2004 - 12/31/2023 Active Number MD25233
III. PROFESSIONAL EXPERIENCE
Academic (Include Year, Position, and Institution):
9/22/1998 - 1/21/2003 Assistant Professor, Internal Medicine/Division of Hematology-Oncology, University of Michigan, Ann Arbor, MI
9/22/1998 - 1/23/2004 Staff Physician, Internal Medicine-Hematology/Oncology, VA Ann Arbor Health Care System, Ann Arbor, MI
1/22/2003 - 1/23/2004 Clinical Assistant Professor, Internal Medicine-Hematology/ Oncology, University of Michigan, Ann Arbor, MI
2/2004 – 6/2016 Assistant Professor Internal Medicine-Hematology/Oncology, Oregon Health Sciences University, Portland, OR
2/2004 – 9/2017 Staff Physician, Hospital and Specialty Medicine, VA Portland Health Care System, Portland, OR
7/2016 – ongoing Associate Professor Internal Medicine-Hematology/Oncology, Oregon Health Sciences University, Portland, OR
Administrative (Include Year, Position, and Institution):
2001 - 2004 Representative, Faculty Senate Assembly, University of Michigan
2001 - 2004 Co-director, Cutaneous T-cell Lymphoma Program, University of Michigan
2018- Co-Chair, Clinical Knowledge and Therapeutics Executive Committee – Oncology subcommittee
Other (Include Year, Position, and Institution):
IV. SCHOLARSHIP
Area(s) of Research/Scholarly Interest: My clinical and research are focused on lymphoma with a special emphasis on T cell lymphomas and immunotherapy.
Grants and Contracts:
Federal (Include Title, Source, PI, Amount Period, and % Effort)
Title: “Tumor TCR Idiotype Vaccines for Active Immunotherapy of T Cell Cancers”
Source: Veterans Affairs MERIT Review Award
Principal Investigator: Craig Okada
Amount of $591,700 (direct costs)
Period: 9/01 - 8/05
Effort: 35%
State and Local (Include Title, Source, PI, Amount Period, and % Effort)
Title: “Development of T cell tumor TCR Id vaccines for clinical studies”
Source: Veterans Education and Research Association of Michigan
Principal Investigator: Craig Okada
Amount: $15,000 (direct costs)
Period: 6/1999 - 5/2000
Effort: 20%
Title: “Enhanced Dendritic Cell Vaccine Efficacy by Improving Lymph Node Homing” Source: Medical Research Foundation of Oregon
Principal Investigator: Craig Okada
Amount of $30,000 (direct costs)
Period: 6/05 - 5/06
Effort: 35%
Other Support (Include Title, Source, PI, Amount Period, and % Effort)
Title: “Development of T Cell Tumor TCR Id Vaccines”
Source: American Cancer Society Institutional Award
Principal Investigator: Craig Okada
Amount: $25,000 (direct costs)
Period: 7/1999 - 6/01
Effort: 25%
Title: “Tumor Antigen Receptor Vaccines for Active Immunotherapy of T Cell
Malignancies”
Source: The G & P Charitable Foundation for Cancer Research
Principal Investigator: Craig Okada
Amount: $150,000 (direct costs)
Period: 8/1999 - 7/2002
Effort: 20%
Title: “Treatment of T cell Lymphomas with T Cell Receptor Specific Antibodies and
Vaccines”
Source: Leukemia & Lymphoma Society
Principal Investigator: Craig Okada
Amount: $411,200 (direct costs)
Period: 10/2006 - 9/2011
Effort: 20%
Pending Support (Include Title, Source, PI, Amount Period, and % Effort)
Publications/Creative Work:
Peer-reviewed
- Elliot GC, Ajioka J and Okada CY. A rapid procedure for assaying nicotinamide phosphoribosyltransferase. Anal. Biochem. (1980) 107:199 - 205.
- Okada CY and Rechsteiner M. Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles. Cell (1982) 29:33 - 41.
- Barth RK, Kim BS, Lan NC, Hunkapiller T, Sobieck N, Winoto A, Gershenfeld H, Okada CY, Hansberry D, Weissman I and Hood L. The murine T - cell receptor uses a limited repertoire of expressed Vb gene segments. Nature (Lond.) (1985) 316:517 - 23.
- Mueller C, Gershenfeld HK, Lobe CG, Okada CY, Bleackley RC and Weissman IL. Expression of two serine esterase genes during an allograft rejection in the mouse. Transplant Proc. (1988) 20:251 - 53.
- Mueller C, Gershenfeld HK, Lobe CG, Okada CY, Bleackley RC and Weissman IL. A high proportion of T-lymphocytes that infiltrate H-2 incompatible heart allografts in vivo express genes encoding cytotoxic T cell specific serine proteases, but do not express the MEL-14 - defined lymph node homing receptor. J. Exp. Med. (1988) 167:1124 - 36.
- Okada CY and Weissman IL. Relative Vb transcript levels in thymus and peripheral lymphoid tissues from various mouse strains. Inverse correlation of IE and Mls expression with relative abundance of several Vb_ transcripts in peripheral lymphoid tissues. J. Exp. Med. (1989) 169:1703 - 1719.
- Okada CY, Holzmann B, Guidos C, Palmer E and Weissman IL. Characterization of a rat monoclonal antibody specific for a determinant encoded by the Vb7 gene segment. Depletion of Vb7+ T-cells in mice with Mls-1a haplotype. J. Immun. (1990) 144:3473 - 3477.
- Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, and Levy R. Rationale for adjuvant idiotypic vaccination after high dose therapy for multiple myeloma. Biol Blood Marrow Transplant (1997) 3:157 - 163.
- Okada CY, Wong CP, Denney DW and Levy R. T cell antigen receptor vaccines for active immunotherapy of T cell malignancies. J. Immun. (1997) 159:5516 - 5527.
- Wong CP, Okada, CY and Levy R. TCR vaccines against T cell lymphoma: QS-21 and IL-4 adjuvants induce a protective CD8+ T cell response. J. Immun. (1999) 162:2251 - 2258.
- Reichardt, VL, Okada CY, Liso A, Benike C, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R. Idiotype vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation. Blood (1999) 93:2411 - 2419.
- Lossos, IS, Okada CY, Tibshirani R, Warnke R, Vose JM, Greiner TC, Allen J, and Levy R. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood (2000) 95:1797 - 1803
- Reddy SA. Okada C, Wong C, Bahler D, Levy R. T cell antigen receptor vaccines for active therapy of T cell malignancies. Annals of the New York Academy of Sciences (2001) 941:97- 105.
- Timmerman JT, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, and Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 99: 1517 - 1526
- Gatza E and Okada CY. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J. Immun. (2002) 169:5227 - 5235
- Lambert SL, Okada CY, Levy R. TCR vaccines against a murine T cell lymphoma: A primary role for antibodies of the IgG2c class in tumor protection. J. Immunol. (2004) 172:929 - 936
- Lau JJ. Okada CY. Trobe JD. Galloping ophthalmoplegia and numb chin in Burkitt lymphoma. J. Neuro-Ophth. (2004) 24(2):130 - 4.
- Gatza E and Okada CY. Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for T cell lymphoma. Cancer Immunology & Immunotherapy (2006) 55(4):420 - 32. (UI: 16025264)
- Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, and Shuman M. Gene expression and angiotropism in primary CNS lymphoma. Blood (2006) 107: 3716 - 3723. (UI: 16418334)
- Spurgeon SE, Pindyck T, Okada C, Chen Y, Chen Z, Mater E, Abbi K and Epner EM. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leukemia and Lymphoma (2011) 52(8): 1488 – 1494. (UI: 21623691)
- Smith SD, Chen A, Spurgeon S, Okada C, Fan G, Dunlap J, Braziel R and maziar R. Diffuse large B cell lymphoma in adults aged 75 years and older: a single institution analysis of cause-specific survival and prognostic factors. Therapeutic Advances in Hematology (2013) 4(6):349-53
- Chen AI, Okada C, Gay N, Reiss P, Spurgeon S, Fan G, Braziel RM and Maziarz RT. Consolidative autologous stem cell transplant for double hit lymphoma. Blood (2014) 3993-
- Gay ND, Okada CY, Chen AI and Scott EC. Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab. Therapeutic Advances in Hematology (2017) 8(5):175-180). PMID: 28473905
- Chen, AI, Leonard, JT, Okada, CY, Gay ND, Chansky, K, Fan G, Dunlap JB and Raess, PW. Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma. Leukemia & Lymphoma (2018) 59:1884-1889. PMID: 29199519
- Gay ND, Kozin E. Okada C, Danilov AV, and Spurgeon S. Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia. Leukemia & Lymphoma (2018) 59:2258-2260 PMID 29249186
- Gay ND, Chen, A and Okada CY. Colorectal lymphoma: a review. Clinics in Colon and Rectal Surgery. (2018) 31:309-315
- Best S, Hashiguchi T, Kittai A, Bruss N, Paiva C, Okada C, Liu T, Berger A and Danilov AV. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells. Blood Advances (2019) 3:51-62. PMID 2018026880
- Johnson LDS, Banerjee S. Kruglov O, Viller NN, Horwitz SM, Lesokhin A, Zain J, Quefeld C, Chen R, Okada C, Sawas A, O’Connor OA, Sievers EL, Shou Y, Uger RA, Wong M, Akilov OE. Targeting CD47 in Sezary syndrome with SIRPalphaFC. (2019) Blood Advances 3(7):1145-1153
- Willis A, Fan G, Kim E, Okada CY, White KP and Hopkins RS. Primary cutaneous Epstein-Barr virus-positive diffuse large B cell lymphoma (DLBCL) in a patient taking fingolimod. Dermatology Online Journal. 25(9), 2019 Sep 15
- Hashiguchi T, Bruss N, Lam V, Danilova O, Paiva CJ, Wolf J, Bilvert EW, Okada CY, Kaur P, Drew L, Cidado J, Hurlin P and Danilov AV. Cyclin-Dependent Kinase-9 is a therapeutic taret in Myc-expressing diffuse large B cell lymphoma. Molecular Cancer Therapeutics (2019) 18(9):1520-1532
- Johnson LDS, Banerjee S, Kruglov O, Viller NN, Horwitz SM, Lesokhin A, Zain J, Quefield C, Chen R, Okada C, Sawas A, O’Connor OA, Sievers EL, Shou Y, Uger RA, Wong M, Akilov DE. Targeting CD47 in Sezary syndrome with SIRPalphaFc. Blood Advances. (2019) 3(7);1145-1153
- Raghunathan V, Fan G, Kittai AS, Okada C, Danilov AV, Spurgeon SE. A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia. (2020) European Journal of Haematology Epub Ahead of Print. Web. 11 January. 2021
Non-peer-reviewed: none
Books: none
Chapters
- Okada CY, Traer E and Dunlap J. Classical Hodgkin Lymphoma with Paraneoplastic Neruomytonia. In Case Studies in Hematology and Coagulation. p216 - 218. Ed: Gulati G, O’Hara JF and Krause JR. AACP Press 2012
- Okada CY, Gang XU. Lymphocyte-Rich Classical Hodgkin Lymphoma. In Case Studies in Hematology and Coagulation. p222 - 224. Ed: Gulati G, O’Hara JF and Krause JR. AACP Press 2012
Electronic Publications: none
Reviews
- Adkins B, Mueller C, Okada CY, Reicherst RA, Weissman IL and Spangrude GJ. Early events in T-cell maturation. Ann. Rev. Immunol. (1987) 5:325 - 65.
- Okada C, New small lymphocytic lymphomas. Michigan Oncology Journal Fall, 2000:8 - 10
Abstracts
- Duvic M, Vanaclocha F, Bernengo MG, Okada C, Breneman D, Zinzani PL, Zhang L, Bopp K, Laird G, Harawat S and Prince M. Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory cutaneous T cell lymphoma (CTCL). ASCO (2008) J. Clin. Oncol. 26 Absr 8555
- Pindyck T, Spurgeon SE, Okada CY and Epner EE. Cladribine plus rituximab for the initial treatment of mantle cell lymphoma. ASCO (2010) J. Clin. Oncol 28:15s abstr 8099.
- Spurgeon SE, Okada CY, Huang J, Phillips J, and Epner EE. Targeting the epigenome: A phase I/II study of vorinostat (SAHA), CLADRIBINE (2-CDA), and rituximab in relapsed B cell malignancies. ASCO (2010) J. Clin. Oncol 28: 15s Absr TPS301
- Spurgeon S, Pindyck T, Loriaux MM, Okada C, Abbi K, Chen Y, Chen Z, Mater E and Epner E. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Blood 2010, 116: Abs 4910
- Crump M, Scheliga A, Mayer J, Offner F, Teixeira A, Kuliczdowski K, Liberati AM, Okada C, Esseltine D-L, Enny C, Zhu E. van de Velde H, Elsayed YA, and Coiffier B. Efficacy and safety of bortezomib-rituximab (VcR) vs rituximab (R) in patients (pts) with relapsed, R-naïve/-sensitive follicular lymphoma (FL) who had received 1 or 2 prior lines of therapy. ICML 2011 congress
- Kimby E, Scheliga A, Mayer J, Offner F, Teixeira A, Kuliczdowski K, Liberati AM, Okada C, Esseltine D-L, Theocharous P, Zhu E. van de Velde H, Elsayed YA, and Coiffier B. Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VcR) vs rituximab (R) in patients (pts) with relapsed follicular lymphoma (FL). ICML 2011 congress
- Zinzani PL, Khuageva NK, Wang H, Garikochea B, VanHoof A, Soubeyran P, Caballero D, Okada C, Buckstein R, Esseltine D-L, Theocharous P, Zhu E, Eenny C, Elsayed YA, and Coiffier B. Bortezomib plus rituximab (VcR) vs rituximab alone (R) in patients (pts) with high-risk, relapsed, R-naïve/-sensitive follicular lymphoma (FL). ICML 2011 congress
- Spurgeon S. Chen AI, Okada C, Parekh S, Leshchenko VV, Palmbach G, Ratterree B, Subbiah N, Capper C, and Epner EM. A phase I/II study of vorinostat (SAHA), cladribine (2-CdA), and rituximab shows significant activity in previously untreated mantle cell lymphoma. Blood 2011, 118: Abstr 441.
- Smith SD, Okada C, Chen AI, Spurgeon SE, Fan G, Dunlap JB, Leeborg N, Braziel RM and Maziarz RT. Prognostic features, treatments and disease-specific mortality among patients with diffuse large B-cell lymphoma over the age of 75: A single-center retrospective analysis. Blood 2012, 120: abstr 3673
- Flowers, C Panizo C, Isufi I, Herrera F, Okada C, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J Chau I, von Keudell GR, Lu H, Hsu FJ and Halwani AS. Blood 2017, 130:2771
Other
Clinical Investigation Activities (Principle Investigator Only)
1999 - 2004 “A Phase 3 Trial to Evaluate the Safety and Efficacy of Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH with GM-CSF, Compared to Non-Specific Immunotherapy, KLH with GM-CSF, in Patients with Follicular Non-Hodgkin’s Lymphoma” Sponsor: Genitope Corp.
2007 - 2009 “Hx-CD4-110: Open-label, Dose escalation, followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides type CTCL (stage IB-IVB) who are Refractory or Intolerant to Targretin® (bexarotene) and one other Standard Therapy” Sponsor: GenMab
2007 - 2009 “A Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-Cell Lymphoma” Sponsor: Novartis
2007 - 2008 “Favid-06: A Phase III, Randomized, Double Blind, Placebo Controlled Trial of Favid and GM-CSF versus Placebo and GM-CSF Following Rituximab in Subjects with Follicular B-Cell Non-Hodgkin’s Lymphoma” Sponsor: Favrille
2007 - 2008 “Favid-09: A Phase II Trial of Favid (Patient-Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive Favid on Study Favid-06” Sponsor: Favrille
2007 - 2010 “E4494: Phase III Trial of CHOP versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients with Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin’s Lymphoma” Sponsor: SWOG
2007 - 2010 “A Randomized, Open-Label Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab Naïve or Sensitive Follicular B-Cell Non-Hodgkin’s Lymphoma” Sponsor: Johnson & Johnson Pharmaceutical
2007 - 2008 “S9911: A Phase II Pilot Trial of CHOP Followed By Iodine-131-Labeled Monoclonal Anti-B1 Antibody For Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphomas” Sponsor: SWOG
2007 - 2010 “A Double-Blind, Randomized, Two-Dose-Arm, Parallel Group, International, Multi-Center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients with Follicular Lymphoma who are Refractory to Rituximab in combination with Chemotherapy” Sponsor: Genmab, Inc.
2008 - 2011 “An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High Risk Diffuse Large B-Cell Lymphoma” Sponsor: Eli Lilly and Company
2008 - 2011 “S8819: Central Lymphoma Repository Tissue Procurement Protocol. A companion Protocol.” Sponsor: SWOG
2008 - 2010 “A Phase I/II Study of Oral Clofarabine + Rituximab in Relapsed B Cell NHL” Sponsor: Genzyme
2010 - 2011 “An Open-Label Study to Evaluate the Efficacy and Safety of Treatment with Bendamustine in Combination with Ofatumumab in Previously Untreated Patients with Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)” Sponsor: Cephalon
2011 - 2013 “Phase II trial of ofatumumab and bortezomib in subjects with relapsed CD20+ Diffuse Large B Cell Lymphoma, Follicular Lymphoma, or Mantle Cell Lymphoma” Investigator Initiated study. Support: GSK
2011 - 2017 “A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging” Sponsor: SWOG
2011 - 2017 “Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomograph for Non-Bulky Stage I and II Hodgkin Lymphoma” Sponsor: CALGB
2015- 2019 “Phase 1/2 Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma” Sponsor: Immune Design
2018 - ongoing “A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors” Sponsor: Trillium Therapeutics Inc
2018 - ongoing “A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B cell Lymphoma” Sponsor: F. Hoffmann-La Roche.
2019 – ongoing “A Phase III, Randomized Study of Nivolumab (Opdivo) plus AVD or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age ≥ 12 Years) with Newly diagnosed Advanced Stage Classical Hodgkin Lymphoma.” Sponsor: NCI CIRB
2019 – 2020 “ A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapeis.” Sponsor: MEI Pharma Inc
2019 – ongoing “An Open label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K d/g Dual Inhibitor, Given in Combination with a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients with Relapsed/Refractory T cell Lymphoma.” Sponsor: Rhizen Pharmaceuticals
2020 – ongoing “Randomized Phase II/III Study of Venetoclax (ABT 199) plus Chemoimmunotherapy for Myc/BCL2 Double-Hit and Double Expressing Lymphoma” Sponsor: Alliance for Clinical Trials in Oncology
2020 – ongoing “Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas” Sponsor: Astex Pharmaceuticals
Invited Lectures, Conference Presentations or Professorships:
International and National (Past 10 years only)
8/11/2009 “Epigenetics, New Insights into Cancer”, Nebraska Oncology Society, Omaha Nebraska
02/01/2010 “ONTAK (denileukin diftitox) – Results from the Largest Phase III Randomized, Placebo-Controlled, Double Blinded Trial in CTCL” Medical Oncology-Hematology Division Ground Rounds, Rush University, Chicago IL
1/9/2012 “Cutaneous T cell lymphoma (CTCL) and the Role of Extracorporeal Photopheresis (ECP)” North Shore University Hospital, New York, NY
Regional and Local (Past 10 years only)
5/13/2009 “What’s new in the treatment of Non-Hodgkin lymphoma” at the Leukemia & Lymphoma Patient Education Talks. Portland, Oregon
11/23/2009 “Introduction to Lymphoproliferative Disorders” at the Internal Medicine House Staff Noon Lectures
12/10/2009 “Follicular Lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR
1/22/2010 “Update in Lymphoma” at the 10th Annual Hematology and Breast Cancer Update, Portland Oregon
1/29/2010 “Marginal Zone Lymphomas” at the OHSU Hematology/Oncology Fellow’s Grand Rounds, Portland OR
2/25/2010 “Reprograming Gene Expression and Protein Activity: Insights on Histone Deacetylase in Cancer” Coos Bay, Oregon
4/24/2010 “Chronic Lymphocytic Leukemia 2009-2010” at the Leukemia & Lymphoma Patient Education Seminar, Portland, Oregon
9/6/2010 “HDAC inhibitors for Cutaneous T Cell Lymphoma”, Salem Oregon
1/14/2011 “Update in Lymphoma” at the 11th Annual Hematology and Breast Cancer Update, Portland Oregon
10/5/2011 “Imaging in Lymphoma” at the OHSU Leukemia and Lymphoma Conference, Portland OR
12/21/2011 “T cell Lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR
1/20/2012 “Update in Lymphoma” 12th Annual Hematology and Breast Cancer Update, Portland Oregon
1/31/2012 “Introduction to Lymphoproliferative Disorders” at the Internal Medicine House Staff Noon Lectures.
3/14/2012 “Burkitt’s Lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR
3/21/2012 “Update on Cutaneous Lymphoma” at the Oregon Dermatology Society Meeting.
7/18/2012 “Paraneoplastic Neuropathy” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR
11/8/2012 “Indolent Lymphoma” at the OHSU Hematology/Oncology Fellow’s Grand Rounds, Portland OR
11/8/2012 “Ask about Lymphoma” at the Lymphoma Research Foundation Patient Education forum, Portland, Oregon
12/12/2012 “Peripheral T cell lymphoma” OHSU Community Oncology, Beaverton OR
12/18/2012 “Lymphoma Treatment in Pregnant Patients” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR
1/18/2013 “Update in Lymphoma” at the 13th Annual Hematology and Breast Cancer Update , Portland Oregon
4/22/2013 “Lymphoma Treatment in Pregnant Patients” at the Maternal Fetal Medicine Conference, OSHU, Portland, Oregon
4/25/2013 “T cell Lymphoma” at the OHSU Hematology/Oncology Fellow’s Grand Rounds, Portland OR
6/26/2013 “CNS Lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR
9/18/2013 “Immunotherapy Treatments for Lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR
5/14/2014 “Chemotherapy and Radiation Treatment of Lymphoma” at the Radiation Oncology Lecture Series, OHSU, Portland, Oregon
5/28/2014 “Update on Cutaneous T Cell Lymphoma” at the City Wide Dermatology Conference, OHSU, Portland, Oregon
7/17/2014 “Introduction to Lymphoma” at the OHSU Oncology Nurses Education series, Portland OR
10/8/2014 “Post Transplant Lymphoproliferative Disorder” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR
11/14/14 “Indolent Lymphoma” at the OHSU Hematology/Oncology Fellow’s Grand Rounds, Portland OR
1/7/2015 “Epstein Bar Virus (EBV) infections and Hemophagocytic lymphohistiocytosis (HLH)” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR
1/16/2015 “Update in Lymphoma” at the 14th Annual Hematology and Breast Cancer Update, Portland Oregon
1/23/2015 “T cell Lymphoma” at the OHSU Hematology/Oncology Fellow’s Grand Rounds, Portland OR
1/29/2015 “Updates from ASH” at the S.W. Washington Oncology Journal Club, , Vancouver WA.
4/6/2015 “Hematology as a Career” at the OHSU Medical Student Oncology Interest Group, Portland OR
4/23/2015 “Post Organ Transplant Malignancies and Cancer screening” at the OHSU Combined Transplant Grand Rounds. OHSU Hospital, Portland OR
6/24/2015 “Hodgkin Lymphoma – Management and New Treatments” at the Legacy Hospital Oncology Grand Rounds. Good Samaritan Medical Center, Portland OR
7/6/2015 “Introduction to Hematology Procedures” at the OHSU Hematology/Oncology Fellowship Orientation week, Portland OR
11/06/2015 “Low grade Lymphoma” at the OHSU Hematology/Oncology Fellow’s Grand Rounds, Portland OR
11/07/2015 “How to Write a Grant” OHSU Fellowship Research Conference, Skamania Lodge, Stevenson, WA
1/15/2016 “Update in Lymphoma” at the 14th Annual Hematology and Breast Cancer Update, Portland Oregon
1/20/2016 “CNS Lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR
2/2/2016 “Lymphoma and Chemotherapy” at the Radiation Oncology Lecture Series, OHSU, Portland, Oregon
6/8/2016 “Burkitt’s lymphoma” at the OHSU Center for Hematologic Malignancies Grand Rounds, Portland OR
7/5/2016 “Introduction to Hematology Procedures” at the OHSU Hematology/Oncology Fellowship Orientation week, Portland OR
6/23/2017 “Hematologic Malignancies – 2017 Updates in Oncology Conference” Sentinel Hotel, Portland OR
7/10/2017 “Introduction to Hematology Procedures” at the OHSU Hematology/Oncology Fellowship Orientation week, Portland OR
8/30/2017 “Treatments for Cutaneous T cell Lymphoma” at the Cutaneous Lymphoma Foundation Patient Education Forum, Portland, OR
1/19/2018 “Update in Lymphoma” at the 16th Annual Hematology and Breast Cancer Update, Portland Oregon
7/20/2018 “Hematologic Malignancies – 2018 Updates in Oncology Conference” Sentinel Hotel, Portland OR
1/18/2019 “Update in Lymphoma” at the 17th Annual Hematology and Breast Cancer Update, Portland Oregon
6/14/2019 “Hematologic Malignancies – 2019 Updates in Oncology Conference” Sentinel Hotel, Portland OR
11/20/2019 “Hodgkin Lymphoma” at OHSU CME Talks, Portland OR
11/27/2019 “B cell lymphoma” at OHSU CME Talks, Portland OR
V. SERVICE
Membership in Professional Societies:
1986 - 2000 American Medical Association
1991 - ongoing American College of Physicians
1993 - ongoing American Society of Hematology
1994 - ongoing American Association for the Advancement of Science
1998 -2005 American Society of Clinical Oncology
2000 - 2004 Central Society for Clinical Research
2012 - ongoing Oregon Medical Society
Granting Agency Review Work:
2/2000 NIH Ad Hoc Member Site Visit Review - Memorial Sloan Kettering Cancer Center Gene Therapy Program, New York NY
11/2010 NIH PAR 01-045 and PAR 01-046, Cancer Molecular Target Drug Discovery, Bethesda MD
10/2012 NIH PAR 12-144, Cancer Molecular Target Drug Discovery, Bethesda MD
3/2010 - 4/2014 NIH SBIR Topic 255, Development of Anticancer Agents Technical Emphasis Panel, Bethesda MD
6/15/2016 NIH SBIR Topic 326: Development of Novel Therapeutic Agents that Target Cancer Stem Cells
11/15/2018 NIH SBIR Phase IIB Bridge Awards – Cancer Therapeutics and Preventative Agents, Cancer Imaging Technologies. Interventional Devices.
Editorial and Ad Hoc Review Activities:
2001 - 2009 Online Update Editor for Kelly Textbook of Internal Medicine
2007 - 2011 Ad Hoc Reviewer for International Journal of Laboratory Hematology
2007 - 2010 Ad Hoc Reviewer for Cancer Letters
2010 - 2011 Ad Hoc Reviewer for Blood
2014 Ad Hoc Reviewer for Journal of Hematology Research
Committees:
International/National
Regional
Institutional
1998 - 2004 Member, Blood Utilization Committee, Veteran Administration Ann Arbor Healthcare Systems
1999 - 2004 Member, Immunology Graduate Program, University of Michigan
1999 - 2004 Member, Tumor Immunology Program, University of Michigan
2000 - 2004 Member, MSTP Career Advisory Panel, University of Michigan
2002 - 2004 Member, Cancer Committee, Veteran Administration Ann Arbor Healthcare Systems
2002 - 2004 Member, Research and Development Committee, Veteran Administration Ann Arbor Healthcare System, Ann Arbor, MI
2005 - 2006 Alternate Member, Research and Development Committee, VA Portland Health Care System, Portland, Oregon
2007 - 2010 Member, Research and Development Committee, VA Portland Health Care System, Portland, Oregon
2010 - 2013 Alternate Member, Research and Development Committee, VA Portland Health Care System, Portland, Oregon
2011 - ongoing Member, Clinic Research Review Committee, Oregon Health & Sciences University, Portland, Oregon
2012 - ongoing Member, Joint OHSU/VA Institutional Review Board, Oregon Health & Sciences University and VA Portland Health Care System, Portland, Oregon
2013 - 2018 Member, Pharmacy and Therapeutics – Oncology Subcommittee. Oregon Health and Sciences University
2014 - 2016 Member, Pharmacy and Therapeutic Committee, VA Portland Health Care System, Portland, OR
2018 - ongoing Co-chair, Pharmacy and Therapeutics – Oncology Subcommittee. Oregon Health and Sciences University
2018 - ongoing Member, Clinical Knowledge and Therapeutics Executive Committee, Oregon Health and Science University
Departmental
2007 - 2015 Member, Hematology-Oncology Fellowship Selection Committee, Oregon Health and Science University, Portland, Oregon
2007 - ongoing Interviewer, Intern Applicants, Department of Intern. Med., Oregon Health and Science University, Portland, Oregon
2009 - ongoing Lead, Lymphoma Tumor Board, Oregon Health and Science University, Portland OR
Community Service:
Patient education forums:
9/16/2000 Cure for Lymphoma Living Well with Lymphoma Family Forum “Orphan Lymphomas” Novi, MI
5/23/2001 "Ask the Doctor about Lymphoma" Gilda's Club, Royal Oak, MI
10/10/2007 OHSU and Cutaneous Lymphoma Foundation Patient Education Forum “Cutaneous Lymphomas Overview” and “CTCL Diagnosis, Staging and Prognosis”. Portland, Oregon
5/13/2009 Leukemia & Lymphoma Patient Education Talk. “What’s new in the treatment of Non-Hodgkin lymphoma” Portland, Oregon
4/24/2010 Leukemia & Lymphoma Patient Education Symposium, “Chronic Lymphocytic Leukemia 2009-2010” Portland, Oregon
11/8/2012 Lymphoma Research Foundation “Ask about Doctor” Update on Follicular Lymphoma. Center for Health and Healing, Portland, Oregon
2/21/2017 Lymphoma Research Foundation “Ask the Doctor” Update on Mantle Cell Lymphoma, Portland Oregon
3/15/2017 Cutaneous Lymphoma Foundation Patient Education Forum “Update in Cutaneous T cell Lymphoma”. Tualitin, Oregon
8/30/2017 “Treatments for Cutaneous T cell Lymphoma” at the Cutaneous Lymphoma Foundation Patient Education Forum, Portland, OR
6/23/2019 Clinical Trials in Cutaneous Lymphoma” at the Cutaneous Lymphoma Foundation Patient Education Forum, Los Angles, CA
Clinical Responsibilities (since last promotion):
9/1998 - 1/2004 Staff Physician, Hematology Outpatient Clinic, VA Ann Arbor Healthcare System, Ann Arbor, MI
9/1999 - 1/2004 Attending Physician, Hematology Consult Service, University of Michigan
9/1999 - 1/2004 Staff Physician, Hematology Consult Service, VA Ann Arbor Healthcare System
9/1999 - 1/2004 Attending Physician, Lymphoma Multidisciplinary Clinic, Univ. of Mich.
10/2000 - 1/2004 Attending Physician, Cutaneous T cell Lymphoma Clinic, Univ. of Mich.
2/2004 – 10/2017 Staff Physician, Hospital and Specialty Medicine - Hematology, VA Portland Health Care System, Portland, OR
7/2004 - ongoing Attending Physician, Hematology Consult Service and Malignant Hematology Service, Oregon Health & Science University, Portland, OR
7/2004 - ongoing Attending Physician, Cutaneous Lymphoma Clinic, Oregon Health & Sciences University, Portland, OR
6/2007 - ongoing Attending Physician, Lymphoma Clinic, Oregon Health & Sciences University, Portland, OR
6/2009 - ongoing Attending Physician, Malignant Hematology Inpatient Hospital Service, Oregon Health & Science University, Portland, OR
7/2015 – 10/2017 Staff VA Portland Health Care System Hem/Onc Fellow’s clinic
VI. TEACHING:
Overview of your Role as an Educator: (see OHSU Educators Portfolio)
5/24/2019 Faculty Teaching Award from the Internal Medicine Housestaff
Scholarship of Teaching:
Curriculum Development
2015 – Member, Hematology and Medical Oncology Fellowship Curriculum Committee, Oregon Health & Science University
Educational Publications
Educational Conference Presentations
Education Grants and Contracts:
Educational Activity (see Appendix A and B):
1999 - 2003 Lecturer, Hematology/Oncology Research Conference, “TCR Idiotype Vaccine for the Treatment of T cell Malignancies.” University of Michigan
1999 - 2003 Lecturer, Hematology Noon Conference, “Cases from the Hematology Consult Service” University of Michigan
2001- 2003 Group Leader, PIBS 501 – Research Responsibility, University of Michigan
2002 Lecturer, Internal Medicine Noon Conference, “Approach to the Patient with Thrombocytopenia”, University of Michigan
2002 Lecturer, Immunology 850 - Special Topics in Immunology, “Idiotype Vaccines for Treatment of Lymphoid Malignancies”. University of Michigan
2004 - 2014 Lecturer and small group session leader, Pathophysiology of Blood, Oregon Health & Science University
2005 - ongoing Clinic Mentor for PCM student (1st and 2nd year medical student), Oregon Health & Sciences University
2007 - 2013 Small group session leader, Biologic Basis of Disease, Oregon Health & Science University
2007 - 2010 Lymphoma case conference –Every other week conference on interesting lymphoma cases. Oregon Health & Science University
2007 - ongoing Lecturer, Noon Conference for Internal Medicine Housestaff, Lecture on Lymphoma. Oregon Health & Science University.
2007 - ongoing Lecturer, Hem-Onc Fellow Grand Rounds, Oregon Health & Science University
2009 - ongoing Lecturer, Medical Student Core Lectures, Oregon Health & Science University
- Introduction to lymphoproliferative disorders
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia (occasionally)
2009 - ongoing Lead, Lymphoma Tumor Board, Oregon Health & Science University
2009 - ongoing Lecture in Cancer Biology CELL616 course
2009 - ongoing Lecture, Noon Conference for Dermatology Housestaff, Oregon Health & Science University
2011- ongoing Speaker, Center for Hematologic Malignancy Grand Rounds, Oregon Health & Science University
12/16/2014 “Ward walk” with 1st and 2nd year medical students
Effectiveness of Educational Activity:
Service and Membership of Educational Committees:
2007- 2017 Hematology and Medical Oncology Fellowship committee
Honors and Awards for Education:
2015 OHSU Hematology and Medical Oncology Annual Teaching Award
Collaborative Skills:
Professional Development in Education:
Financial relationships
-
Type of financial relationship:There are no financial relationships to disclose.Date added:11/28/2022Date updated:10/24/2023